n.a. (RCPT)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Don't Abandon the Biotech Ship

Don't Abandon the Biotech Ship

There's too much good out there.

Drug Stocks' Earnings Power Won't Go Away

Before you sell them, ask yourself at what multiple you sell.

Think Stocks Are Tough? Try a Fantasy Draft

Think Stocks Are Tough? Try a Fantasy Draft

Pick stocks the way you would pick players.

How China's Troubles Affect Biotech and Pharma Stocks: Part 2

How China's Troubles Affect Biotech and Pharma Stocks: Part 2

Currencies and other headwinds come into play.

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

Investors are most excited about Bluebird Bio (BLUE) and Pacira Pharmaceuticals (PCRX), according to Wedbush Securities, which is holding its annual healthcare investment conference in New York.

Grading the Bull Charts for July

Grading the Bull Charts for July

The "A" mark was hit by seven, but only one got a "B".

Celgene Buying Opportunity on the Way?

Celgene Buying Opportunity on the Way?

For frustated bulls, a looming pullback in CELG would create a low-risk entry point.

When Leader Goes Down, Whole Sector Feels It

Biogen's weak numbers leave biotechs ailing.

What Are Portfolio Managers Afraid Of?

What Are Portfolio Managers Afraid Of?

They should learn to trust techs, financials.

Why I Won't Chase Netflix or Celgene Now

Why I Won't Chase Netflix or Celgene Now

It's like buying at the top -- and I don't like buying at the top.

Cramer: AK Steel Is a Casualty of the Euro, Celgene Is Not a Sell

Cramer: AK Steel Is a Casualty of the Euro, Celgene Is Not a Sell

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

You Can Still Buy Celgene at This Level

You Can Still Buy Celgene at This Level

It's just beginning a breakout.

Market Wrap: Stocks Break String of Up Days

Market Wrap: Stocks Break String of Up Days

The energy and materials sectors dragged the averages lower.

Market's Not in the Mood to Move

Market's Not in the Mood to Move

Attention turns to earnings and away from Greece, Fed.

More Stocks to Watch on A Slow Day

It's a very boring session with a narrow trading range as investors take break after four days of rally mode to digest Federal Reserve Chair Janet Yellen's latest comments. Some stocks of interest: Barclays moved Las Vegas Sands (LVS) to Overweight ...

Stocks Edge Higher as Yellen Speaks; Guess? Jumps on CEO Exit

Stocks Edge Higher as Yellen Speaks; Guess? Jumps on CEO Exit

Guess? (GES) shares were rallying after co-founder Paul Marciano announced he is stepping down as CEO effective August.

Biotech Bubble? Works for Me!

The market is posting slight gains as European markets head to a close. Not much reaction so far to Fed chief Janet Yellen's testimony before Congress today. Biotech continues to move higher, almost touching all-time highs on a daily basis recently....

Flat Start, but Celgene Shines

The market opens flat as we try for five days in a row of gains for first time in 2015. Celgene (CELG) has a strong start as several analysts raise price targets after its announcement of the planned acquisition of Receptos (RCPT) and the company ra...

Expect Strength in Biotech Today

We are a half-hour before the open and it looks like we'll start off slightly higher based on current pre-market futures. Biotech could be strong again today on the back of the big acquisition by Celgene (CELG) of Receptos (RCPT) for just over $7 bi...

Day Ahead: Awaiting the Greek Parliament's Vote

Day Ahead: Awaiting the Greek Parliament's Vote

BlackRock and Bank of America also lead today's earnings parade.

Looking for the Next Receptos Is Plain Stupid Right Now

Looking for the Next Receptos Is Plain Stupid Right Now

These stocks will be up so high today, that many fans will say "no thanks."

The Trader Daily: Think Yellen Will Comment on Biotechs Again? Not Likely

The Trader Daily: Think Yellen Will Comment on Biotechs Again? Not Likely

If you're feeling bearish, don't base your posture on weak volume.

At $7.2 Billion, Receptos Is a Steal of a Deal

At $7.2 Billion, Receptos Is a Steal of a Deal

It was too good to pass up for Celgene.

Jim Cramer: Expect Decline in Apple but Don't Trade It

Jim Cramer: Expect Decline in Apple but Don't Trade It

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange. He weighs in on Apple (AAPL), Alcoa (AA), Walgreens (WBA), Disney (DIS) and more.

Bull Chart of the Week: Receptos

Bull Chart of the Week: Receptos

Its recent run is huge, but it doesn't look like it is done here.

Biotech Is Alive and Well With Receptos

Biotech Is Alive and Well With Receptos

Receptos' stock just reached an all-time high on good turnover.

This Is Still a Time for Selling, Not Buying in the Stock Market

This Is Still a Time for Selling, Not Buying in the Stock Market

I wonder why skepticism disappears so quickly these days.

Biotech Stocks Are Booming

Biotech Stocks Are Booming

I like BioMarin because it has more upside and solid Relative Strength.